To register for the Free SmallCapReview Newsletter visit http://www.smallcapreview.com/subscribe.htm.
AM Oil Resources & Technology Inc. (OTCBB: AMOR) Closed at $0.82. Announced yesterday that the Company has adopted a strategy of pursuing air time and space on print and media outlets to increase awareness of its patented products and technologies for maximizing crude oil recovery. The Company is pursuing worldwide application for the use of its Portable Steam Generators in enhanced oil recovery efforts. The fully patented technology has been found to be highly effective in harvesting a greater amount of oil from marginally producing "stripper wells".
What They Do: AM Oil Resources & Technology makes portable steam generators that are designed to maximize oil production in oil fields, both domestically and internationally. This technology is able to recover crude oil that would otherwise remain in the ground forever. The Company believes that its unique approach of applying its proprietary technologies to non-producing oil wells, with known reserves, will earn the company a profitable niche in the petroleum industry. Targeting approximately 480,000 marginal wells in the United States, the Company is ideally positioned to provide an environmentally safe and cost-effective method of maximizing oil production.
How They Trade: AMOR has a 52 week high of $1.01 and a 52 week low of $0.56.
POZEN (Nasdaq: POZN) Closed at $7.47. Today announced today that the U.S. Food and Drug Administration (FDA) has completed its internal discussions and informed the Company that there is no change to previous agreements that gastric ulcer incidence is an acceptable primary endpoint for POZEN’s clinical programs. In October 2008, the FDA had informed POZEN during its review of both the Special Protocol Assessment (SPA) for PA32540 and the Statistical Analysis Plan (SAP) for PN 400 that the FDA was conducting an internal review on the acceptability of gastric ulcers as a primary endpoint in clinical studies.
What They Do: POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN’s efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions.
How They Trade: POZN) has a 52 week high of $14.85 and a 52 week low of $4.61.
Innovative Solutions & Support (Nasdaq: ISSC) Closed at $3.18. Announced yesterday its financial results for the first quarter of fiscal 2009 ending December 31, 2008.
Net revenues for the first quarter of fiscal 2009 were $10.6 million, up 123% from $4.7 million in the first quarter of the previous fiscal year. The Company reported first quarter fiscal 2009 net income of $1.8 million, or $0.11 per fully diluted share, compared to a fiscal first quarter 2008 net loss of ($4.1 million), or ($0.24) per fully diluted share.
Net income and earnings per share for the quarter reflect the reinstatement of the US research and development tax credit during October, 2008, and the reversal of valuation allowances established in fiscal year 2008 based upon projected, current year taxable income. As a result, the effective tax rate for the fiscal first quarter of 2009 was 4%.
What They Do: Innovative Solutions and Support, Inc. and subsidiaries design, manufacture, and sell flat panel display systems, flight information computers, and advanced monitoring systems in the United States and internationally.
How They Trade: ISSC has a 52 week high of $12.61 and a 52 week low of $12.52.
NeuroMetrix (Nasdaq: NURO) Closed at $1.86. Announced yesterday that it has acquired certain technological and intellectual property assets from Cyberkinetics Neurotechnology Systems, Inc. and Andara Life Science, Inc., a wholly-owned subsidiary of Cyberkinetics, for $350,000 in cash.
What They Do: NeuroMetrix is a science-based medical device company advancing patient care through the development and commercialization of innovative products that aid physicians in the assessment, treatment, and repair of peripheral nerve and spinal cord injuries and disorders, and that provide regional anesthesia and pain control.
How They Trade: NURO has a 52 week high of $11.25 and a 52 week low of $0.50.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/subscribe.htm. SmallCapReview has been compensated six thousand dollars by a third party for its efforts in regards to AM Oil Resources & Technology.
